Drugs.com - Clinical Trials

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous...

Feb 9, 2025 - 21:44
 0
Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous...
Read More

Tags:

Previous Article

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Cl...

Next Article

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Pop...

Related Posts

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

Annovis Announces First Patients Entered into Pivotal P...

Feb 9, 2025  0

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Po...

Feb 9, 2025  0

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Merck Announces Phase 3 waveLINE-010 Trial Initiation E...

Feb 9, 2025  0